Current Issue : April-June Volume : 2025 Issue Number : 2 Articles : 2 Articles
This research aimed to improve the delivery of cyclobenzaprine HCl, a drug used for muscle spasms. This drug has low permeability, which limits its effectiveness. To overcome this, the novel delivery system called cubosomes has been used. Cubosomal drug delivery system was preferred due to improved permeability and site-specific action and it carries significant quantity of drug, thus enhancing the permeation of drug. The different non- ionic surfactants namely Poloxamer 407 and GMO were used in different combinations at different ratios for the preparation of cubosomes by constructing Central Composite Design using DoE software. The cubosomes were prepared using top-down technique and evaluated for morphology, drug content, percentage entrapment efficiency and in-vitro release study. Formulation F14 with drug and non-ionic surfactants GMO and Poloxamer 407 in the ratio of 30:4 was found to be optimized formulation based on the values given by DoE. The optimized formulation was further evaluated for SEM, drug content, entrapment efficiency and in-vitro release. The optimized cubosomal formulation (F14) was incorporated into gel for transdermal application and evaluated for spreadability, pH measurement, viscosity measurement, in-vitro drug release and kinetic model studies. The optimized cubosomal gel formulation showed in-vitro drug release of 92.56% at the end of 8th hour. The optimized formulation showed maximum in-vitro drug release which indicates improved drug permeation and thereby a possible enhancement in bioavailability....
In the present study we have prepared bilayer matrix of atorvastatin immediate release and atenolol sustained tablet. Atorvastatin immediate release matrix composed of high amount of starch while Atenolol sustained contains high amount of Kollidon SR and MCC pH 102 which may be possible reason for sustained drug release. The in-vitro drug release of prepared bilayered tablet (FT) was measured and compared with marketed tablet of sustained release atenolol tablet (NOLWIS; Smayan Healthcare Pvt Ltd) which showed fast release of atorvastatin within 45 seconds and sustained release of atenolol over a period of more than 24 hrs. However, the marketed tablet showed complete drug release within 14 hrs. These results revealed that the prepared bilayer tablet have fast releasing ability of atorvastatin and sustained release profile of atenolol....
Loading....